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The type of allergic sensitization is of central importance in the diagnosis and treatment of respiratory allergic diseases.
At least 10% of the general population (and more than 50% of patients consulting for respiratory allergies) are
polysensitized. Here, we review the recent literature on (i) the concepts of polysensitization, paucisensitization,
co-sensitization, co-recognition, cross-reactivity, cross-sensitization, and polyallergy, (ii) the prevalence of
polysensitization and (iii) the relationships between sensitization status, disease severity and treatment
strategies. In molecular terms, clinical polysensitization can be divided into cross-sensitization (also known as
cross-reactivity, in which the same IgE molecule binds to several allergens with common structural features) and
co-sensitization (the simultaneous presence of different IgEs binding to allergens that may not necessarily have
common structural features). There is a strong overall association between sensitization in skin prick tests and
total IgE values but there is debate as to whether IgE thresholds are useful guides to the presence or absence of
clinical symptoms in individual cases. Molecular information from component-resolved techniques appears to
be of value for diagnosis and treatment decisions. Polysensitization develops over time and is a risk factor for
respiratory allergy (being associated with disease severity) and therefore has clinical relevance for treatment
decisions. The subterm polysensitization has been defined as polysensitization to between two and four
allergens. Polyallergy is defined as clinically confirmed allergy to two or more allergens. Single-allergen grass
pollen allergen immunotherapy (AIT) is safe and effective in polysensitized patients, whereas multi-allergen AIT
requires more supporting evidence. Given that AIT may be more efficacious in moderate-to-severe disease than
in mild disease, polysensitization could be an indication for this type of treatment. There is a need for flowcharts
or decision trees for choosing the allergens for AIT in polysensitized patients and polyallergic patients.
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sensitization, Polyallergy, MonosensitizationBackground
Allergic respiratory diseases (including allergic rhinitis
(AR) and allergic asthma (AA)) are major public health
issues, with high prevalence and significant burden [1-5].
The management of respiratory allergy is based on allergen
avoidance (when possible) [6], treatment with symptomatic
drugs (such as antihistamines, inhaled, intranasal and sys-
temic corticosteroids, bronchodilators and leukotriene re-
ceptor antagonists [1,7-9]) and allergen immunotherapy* Correspondence: mlheritier-barrand@stallergenes.com
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unless otherwise stated.(AIT). The latter is a guidelines-supported therapy for
moderate-to-severe AR and mild-to-moderate AA in pa-
tients in whom pharmacological treatment is ineffective,
poorly tolerated or unwanted over the long term [1,2,8,9].
Patients with respiratory allergy may be sensitized and cli-
nically allergic to one or more allergens. There are no
guidelines how to modulate AIT as a function of the num-
ber or nature of the patient’s sensitizations. In the United
States, allergists tend to use mixtures of extracts to treat
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in Europe are typically treated with one or a few allergens
deemed to be most clinically relevant [10-12]. There is an
ongoing debate as to whether single- or multiple-allergen
formulations of AIT should be prescribed.
We reviewed the recent literature in order to (i) iden-
tify definitions of polysensitization, paucisensitization,
co-sensitization, co-recognition, cross-reactivity (also
known as cross-sensitization) and polyallergy, (ii) assess
the prevalence of monosensitization and polysensitization
in the general population and in patients consulting physi-
cians for respiratory allergy, (iii) evaluate the relationship
between sensitization status and the severity of allergic
disease, and (iv) describe the key factors for diagnosis and
treatment.
Methods
MEDLINE, Embase and the Cochrane Library were
searched from January 1999 up until May 2013 using
logical combinations of the following terms (in English
only): allergy; co-sensitization, polysensitization, co-
recognition, cross-reactivity, polyallergy, epitope, multiple-
allergen, multi-allergen, single-allergen, mono-allergen.






Before sensitization to one or more allergens can be dis-
cussed, it is essential to consider the definition of “aller-
gen” itself. In a glossary issued by the European Academy
of Allergy and Clinical Immunology’s Immunotherapy
Task Force, Alvarez-Cuesta et al. defined an allergen as “a
protein or glycoprotein capable of binding immunoglobu-
lin E (IgE)” [13]. A biochemist would consider that an al-
lergen is a protein (such as Der p 1 or Der p 2, the major
allergens from Dermatophagoides pteronyssinus) with a
defined amino acid sequence and three-dimensional struc-
ture. Even then, the Der p 1 produced by D. pteronyssinus
is composed of several variant proteins with slight dif-
ferences in the amino- acid sequence or with other
small (post-translational) modifications [14]. Ultimately,
one must consider antigenic determinants or epitopes –
unique, localized regions on the solvent-accessible surface
of an antigen that are capable of eliciting an immune
response (and subsequently binding IgE). This distinction
explains why cross-sensitization and co-sensitization (as
discussed below) have different molecular bases and fre-
quencies of occurrence. In 2004, Ferreira et al. proposed
the definitions of “cross-reactivity”, “co-sensitization” and
“co-recognition” [15]. They noted that allergen cross-
reactivity is essentially related to similar protein three-dimensional structures and occurs when IgE antibodies
are originally raised against one allergen and then bind
to a similar protein in another allergen; this is also re-
ferred to as “cross-sensitization” in the literature. In
general, more than 70% amino acid sequence identity is
required for cross-reactivity. The authors listed 28
major groups of cross-reactive proteins from various
sources, and stated that the interaction of serum specific
IgEs (ssIgEs) with a cross-reactive, homologous protein
may or may not trigger allergic reactions, depending on
host factors, the allergen in question and the nature of
the exposure. In the case of pollen allergy, if the patient
does not have clear clinical symptoms related to a spe-
cific pollen period, it is impossible to know which of the
two or more cross-reactive proteins the patient was first
exposed to. Hence, Ferreira et al. suggested that the
term “co-recognition” could define the great majority of
IgE reactivity reactions in which the initial sensitizer is not
known. They used the term “co-sensitization” to describe
multiple, unrelated sensitizations to several structurally
unrelated allergen groups. The structural basis of cross-
reactivity was recently confirmed by Pfiffner et al. [16] in
a micro-array study; 3,143 serum samples were tested to
see whether they contained IgE that bound to any of 103
highly purified natural or recombinant allergens immobi-
lized on the array. The researchers confirmed the previous
cross-reactivity data from conventional IgE assays and re-
ported predictions of cross-reactivity based on an iterative,
motif detection algorithm. They hypothesized that cross-
reaction (i.e. a single type of IgE binding to two or more
related motifs) was more common than co-sensitization
(i.e. separate IgEs each binding to different motifs). They
also described a “hierarchy” of allergens within motif
groups and speculated that this might influence the choice
of AIT formulation. These observations also raised the
issue of whether AIT should employ the most frequently
cross-reacting allergen or an allergen that most stringently
cross-reacted with other allergens.
The term “co-recognition” (for IgE reactivity reactions
in which the initial sensitizer is not known) will typically
apply to the particular case of panallergens [17]. These
are groups of evolutionarily conserved proteins found in
many different plant genera and that present a very high
degree of molecular homology. Essentially, each member
of a panallergen family is co-recognized with each other
member. The best-known panallergens are the profilin
proteins, the polcalcin calcium transport proteins, the
lipid transfer proteins and tropomyosin [17]. Although
these panallergens are not highly abundant, the high de-
gree of homology can confound diagnoses. For example,
the ssIgE against the profilin Phl p 12 in subjects with
grass pollen allergy can also bind to Hev b 8 from latex ex-
tract – though this is not associated with clinically rele-
vant latex allergy [18]. Non-protein molecules can also
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drate determinants are glycoprotein-borne asparagine-
linked oligosaccharides that can variously be found in in-
sect venoms, plant pollens, mites, crustaceans and vegeta-
bles [19].
Strictly, “polysensitization” means “more than one
sensitization”, i.e. anything other than monosensitization.
However, we note that de Jong et al. proposed to use the
term “paucisensitization” to describe 2 to 4 sensitizations
and “polysensitization” to describe 5 or more sensitiza-
tions [20]. Although this distinction may be relevant for
certain clinical studies, only a small proportion of patients
consulting allergists will be sensitized to 5 or more aller-
gens, and we consider that “monosensitization” and “poly-
sensitization” are sufficient for clinical use.
In summary, polysensitization can be divided into (i)
cross-reactivity/cross-sensitization (the same IgE binds
to several different allergens with common structural
features) and (ii) co-sensitization (the simultaneous pres-
ence of different IgEs that bind to allergens that may not
necessarily have common structural features). These
relationships will be of importance when considering
component-based diagnostics (CRD). Our definitions of
polysensitization, paucisensitization, co-sensitization, co-
recognition, cross-reactivity/cross-sensitization and poly-
allergy are given in Table 1.
The prevalence of monosensitization and
polysensitization in the general population and in
patients consulting for respiratory allergies
There is a large body of evidence to show that polysensi-
tization (as judged by SPTs or ssIgE assays) is common in
the general population worldwide. In the first European
Community Respiratory Health Survey (ECRHS) of
11,355 subjects, between 57% and 67.8% of the study
population (depending on the country in question) were
not sensitized to any of the test allergens, 16.2% to 19.6%
were monosensitized to one test allergen and 12.8% to
25.3% were sensitized to two or more test allergens [21].
Similar results were obtained in the USA with SPT data
from a sample (n = 10,863) of the general population (aged
from 6 to 59 years) studied in the third National HealthTable 1 Summary of definitions
Term Definition
Polysensitization Sensitization (as confirmed by SPTs or ssIgE assays)
Paucisensitization Polysensitization (as confirmed by specific SPTs or s
Co-sensitization, IgE reactivity reactions in which multiple, unrelated
Cross-sensitization/
cross-reactivity,
IgE reactivity reactions in which IgE antibodies are o
protein in another allergen
Co-recognition A subset of cross-sensitization/cross-reactivity reactio
Polyallergy Clinically confirmed allergy (i.e. specific sensitization
exposure to a specific allergen) to two or more alleand Nutrition Examination Survey: 45.7% were not sensi-
tized to any of the test allergens, 15.5% were monosen-
sitized and 38.8% were polysensitized [22]. A number
of studies (Table 2) have revealed even higher prevalences
of polysensitization in patients consulting physicians for re-
spiratory and food allergies [22-26]. In the study by
Ciprandi et al., clinical symptoms were more severe in
polysensitized patients than in monosensitized patients
[26]. In addition, in a study of SPT results in 3225 AR pa-
tients from Spain and Portugal, the mean ± SD number of
positive tests per patient was 6.5 ± 2 [27]. In a US study of
1338 patients with objectively diagnosed mild-to-moderate
asthma, 81% reacted to three or more allergens [28].
These data make clear that polysensitization is highly
prevalent in allergic patients, although the rates depend
on the population and the region. Patients tend to gain
sensitizations over time. Hence, it is not possible to dir-
ectly compare rates obtained in different studies. Mono-
sensitized subjects may correspond to children who will
become polysensitized later in life or, more rarely, adults
who will never develop additional allergen sensitizations.
In 1999, Silvestri et al. published a study of changes in
allergic sensitization in 165 monosensitized children
with asthma (aged from 18 months to 8 years at enrol-
ment) [29]. All the subjects were tested twice with SPTs
for HDM, pollens, animal dander and moulds at time in-
tervals ranging from 2 to 10 years. It was found that
43.6% of these initially monosensitized children had be-
come polysensitized at their second visit (47.9% of those
aged less than 5 years and 37.3% of the older children).
The changes over time were statistically significant and
varied from one allergen to another: for children initially
monosensitized to HDMs, 45.4% became polysensitized,
whereas the equivalent figure for children initially
monosensitized to pollens was 32.1%. Hatzler et al. stud-
ied the time course of sensitization to Phleum pratense
allergens in the German Multicentre Allergy Study by
collecting ssIgE at the ages of 1, 2, 3, 5, 6, 7, 10, and 13
[30]. The results showed that IgE sensitization at the age
of 3 years predicted AR by the age of 12 years and that a
chronological order for the development of sensitization
to Phl allergens (with Phl p 1 as the initiator in moreto two or more allergens
sIgE assays) to between two and four allergens.
sensitizations arise against structurally unrelated allergen groups.
riginally raised against one allergen and then bind to a similar
ns in which the initial sensitizer is not known.
in SPTs or ssIgE assays and a causal relationship between symptoms and
rgens
Table 2 Studies reporting the prevalence of
polysensitization
Author (reference) Population % of polysensitized
patients
de Jong et al. [22] 9044 children referred to a
central lab for sensitization
testing
27.5%
Migueres et. al. [23] 2714 AR patients 73.5%
Didier et al. [24] 4227 AR patients 62.0%
Navarro et al. [25] 4991 AR patients 31.0%
Ciprandi et al. [26] 2415 AR patients 74.3%
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apparent. An overall assessment of epidemiological and
clinical trial data led a recent review by Calderon et al.
[10] to conclude that 51–81% of patients with allergies
are polysensitized.
The relationship between sensitization and clinical allergy
Sensitization to one or more allergens is highly prevalent
but does not indicate a clinically relevant allergy. When
establishing the clinical relevance of a sensitization, it is
essential to compare the results of SPTs and/or ssIgE as-
says with strong circumstantial evidence (such the pa-
tient’s reporting of the effect of allergen exposure) or a
direct allergen challenge (nasal, conjunctival or bron-
chial) [9]. In a review article published in 2006, the
GA2LEN working group examined factors responsible
for differences between IgE-sensitized asymptomatic
subjects and IgE-sensitized allergic patients [31]. The au-
thors emphasized that among individuals with ssIgE, a
consistent number do not have clinical allergic disease.
For example, 43% of the subjects with ssIgE to inhalant
allergens in the Dutch part of the ECRHS did not
present respiratory symptoms. There are many reasons
for this difference, including a family history of atopy,
levels of total serum IgE and ssIgE or IgG, the epitope
specificity of ssIgEs, monosensitization vs. polysensitiza-
tion, unidentified serum factors, the Treg/Th1/Th2 bal-
ance and IgE receptor polymorphisms and activation
[31]. However, none of these are “all or nothing” factors.
Burbach et al. examined data from 3034 patients in a
multicentre, open, pan-European GA2LEN study [32]
and distinguished between the standardized sensitization
rate (SSR, i.e. all positive SPTs) and the clinically rele-
vant sensitization rate (CCR, in which patients were
asked whether they had symptoms in response to expos-
ure to the allergen). The SSR to a particular allergen ex-
tract varied markedly from one country to another. The
CCR ranged from 50% and 95%, depending on the aller-
gen and country in question. In terms of the relationship
between polysensitization and disease, the risk of AR in-
creased dramatically with the number of sensitizations
and was greatest for children with 5 or 6 sensitizations(adjusted odds ratio (OR): 12.73) and adults with 7 or
more sensitizations (adjusted OR: 21.89. Having 7 or more
sensitizations was also associated with a high risk of AA
(adjusted OR: 6.12 in children and 5.65 in adults) and food
allergy (adjusted OR: 6.93 in children and 2.61 in adults).
The “POLISMAIL” series of studies (for a review, see
Ciprandi et al. [33]) has also characterized the sensitization
status of patients consulting allergists. The first POLIS-
MAIL study evaluated the clinical characteristics of 418
patients with AR. Only 10% of the patients were mono-
sensitized and the mean number of sensitizations at the
start of the study was 2.6 [34]. In another study, the re-
searchers studied serum IgE, IgG, IgG4 and IgA levels for
HDM, birch, grasses and Parietaria allergens in 80 poly-
sensitized patients with AR. The immunoglobulin pattern
differed slightly for each allergen, and a positive correl-
ation between IgE levels and disease severity in the study
population was found [35]. According to de Jong et al, the
strong association between sensitization status and total
IgE values and the striking co-sensitization between bio-
logically unrelated allergens suggest that polysensitization
is the expression of a distinct clinical, more severe, atopic
phenotype, rather than of biological cross-reactivity to
similar allergens [22]. Fasce et al. studied 98 infants (aged
under 12 months at baseline) with onset of wheezing and
concluded that respiratory allergy always starts with
monosensitization [36]. All children underwent SPTs at
baseline and after 2 and 5 years. At baseline, none of the
infants was polysensitized, 20% were monosensitized and
80% were non-sensitized; 5 years later, more than 60% of
the infants were polysensitized or monosensitized (mainly
to HDMs). There was not always a direct relationship be-
tween an increase in the number of sensitizations and the
prevalence of wheezing; some children grew out of their
wheezing but continued to develop sensitizations.
Diagnostic approaches in polysensitized and
polyallergic subjects
When assessing a polysensitized patient, one of the physi-
cian’s main tasks is to establish whether the individual is
truly polyallergic. The diagnosis of distinct clinical allergies
can be facilitated by considering (i) the period during which
the symptoms appear (e.g. spring for tree pollens, early
summer for grass pollens and late summer for weed pol-
lens), (ii) the potential presence of oral allergy syndrome
(e.g. apple oral allergy syndrome is strongly associated with
the presence of an existing birch pollen allergy), (iii) very
large differences in the relative titres of the various ssIgEs
and (iv) the outcome of nasal or conjunctival challenge
tests, if reliably available.
When performed correctly, SPT is an important tool for
the diagnosis of allergy and is highly specific and sensitive
for the diagnosis of sensitization to inhalant allergens.
A positive SPT does not, however, always correlate with
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SPT must always be established before treatment is initi-
ated [32]. Bousquet et al. have stated that despite the over-
all correlation between the degree of IgE sensitization and
the risk of allergic symptoms, IgE thresholds are far from
being absolute guides to the presence or absence of clin-
ical allergy; in addition, some sensitizations are best de-
tected with SPTs and others with ssIgE assays [37].
It is important to consider sensitization to panaller-
gens when reviewing SPT vs. IgE assay results. Orovitg
et al. compared the results of SPTs for grass, tree and
weed pollens with IgE assays (on the ADVIA-Centaur
platform) for specific allergens (including purified panal-
lergens) in 179 polysensitized, pollen-allergic patients in
Spain [38]. Both SPTs and ssIgE assays indicated that
sensitizations to olive and grass pollens were frequent.
The major grass allergen Phl p 5 was identified as a clear
risk factor for panallergen profilin sensitization (OR: 8.3).
The authors concluded that sensitization to panallergens
could be a confounding factor in the diagnosis of polysen-
sitized pollen-allergic patients. In a study of CRD, Barber
et al. found that patients who were simultaneously sensi-
tized to polcalcins and profilins had twice as many sensiti-
zations to major allergens as patients sensitized to only
one group or the other [39].
It is apparent that sensitizations are better dissected
with ssIgE assays than with SPTs. In a study of 494 poly-
sensitized children in whom SPTs had failed to reveal
the causal allergen, Ciprandi et al. noted significant dif-
ferences between the various ssIgE levels tested and thus
suggested that IgE assays are a more appropriate meas-
urement in this context [40]. Technical progress and the
lack of absolute concordance between SPTs and ssIgE
assays have stimulated the development of CRD as a
novel in vitro method for assaying allergen sensitization
[41,42]. This method quantifies ssIgEs that bind to single
allergenic protein components (purified from natural
sources or obtained by recombinant techniques) or even
peptide fragments of allergenic proteins, rather than whole
extracts of native allergens. There is evidence to suggest
that (i) CRD can identify clinically significant ssIgE, (ii)
some sensitization patterns are associated with particular
prognostic outcomes and (iii) CRD can help the physician
to choose the optimal allergen (s) for AIT by differentiating
between cross-reactivity and co-sensitization [16,43].
The use of CRD with purified natural or recombinant
allergens has revealed that a significant number of poly-
sensitized patients have IgE against highly cross-reactive
panallergens (ranging from 10% for calcium binding
proteins to around 40% for profilins) [44]. These obser-
vations define CRD as a complex but promising tech-
nology that will probably replace conventional ssIgE
assays in the near future. Nevertheless, there is a need
for prospective trials to assess the value of CRD forselecting (i) patients for AIT and (ii) the allergens to be
administered [45].
Justicia et al. performed a study on sensitization to
pollen from grasses and the olive tree (which have over-
lapping pollination periods in Spain: April to June and
May to July, respectively) in 1263 patients with positive
SPTs for both [46]. The 88 allergists involved in the
study were first asked to define their choice of the AIT
composition on the basis of the SPT results alone: grass
pollen only in 18% of cases, both grass and olive pollen
in 73% and olive pollen only in 9%. The patients’ serum
samples were then assayed for sslgE against Ole e 1 and
Phl p 1 and the allergists were invited to review the IgE
titres and again recommend the most appropriate AIT.
This resulted in the choice of grass pollen in 30% of pa-
tients, both grass and olive pollen in 35%, olive pollen
only in 16% and no AIT in 19%. Importantly, the “before
IgE” and “after IgE” recommendations differed for 55%
of the patients. This results shows that knowledge of
sensitization status has a major impact on treatment
decisions.
A key remaining issue in the detection of sensitizations
is when to rely on SPTs alone and when to investigate
further with ssIgE assays and CRD. The latter technique
may be of value in patients with positive SPTs for two or
more related allergens. The indications for in vitro diag-
nostic tests are the same as for SPTs. In vitro diagnostic
tests usually show higher sensitivity but lower specificity
and therefore are performed whenever SPTs do not pro-
vide reliable results.
Treatment approaches in polysensitized subjects and
polyallergic subjects
In a recent review, Calderon et al. summarized the conven-
tional treatment strategies for polysensitized subjects in
North America and Europe [47]. In the USA, allergists tend
to prescribe (subcutaneous) AIT formulations comprising
allergens that correspond to all important allergies (or
sometimes only sensitivities) identified in SPTs. As a result,
the AIT formulations used in the USA contain an average
of 8 components [48]. Calderon et al. stated that multi-
allergen immunotherapy (whether administered sub-
cutaneously or sublingually) in polysensitized patients
requires more supporting evidence from well-designed,
well-powered double-blind, placebo-controlled clinical
trials to validate its efficacy in practice. In Europe, the
polysensitized patient is typically treated with the single
allergen (or at most two or three allergens) deemed to
be most clinically relevant. A number of observational
studies performed in Europe have assessed the manage-
ment of polysensitized patients. For example, the fifth
POLISMAIL study was an open assessment of the clin-
ical efficacy of SLIT in 51 polysensitized children (mean
age: 11.8) with AR and/or mild-to-moderate AA [49].
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8% and 6% of cases, respectively (with missing data in
4%). Sublingual AIT was associated with significant re-
ductions in ocular, nasal, and bronchial symptom
scores (p <0.01) and rescue medication use (p <0.01).
There were no systemic reactions in the single-
allergen group or the multi-allergen group. The au-
thors concluded that polysensitization should not rep-
resent a counter-indication for prescribing AIT with
one or two allergen extracts (preferably administered
separately and at high dosage levels). In an overview of
the six POLISMAIL studies, Ciprandi et al. identified
five important aspects for added-value molecular diag-
noses and optimal AIT in polysensitized patients: (i)
rapid, comprehensive assessment of the sensitization
profile, (ii) knowledge of symptoms or diagnostic re-
sults caused by cross-reactivity, (iii) interpretation of
complex sensitization results (e.g. panallergens), (iv)
more accurate identification of candidates for AIT and
(v) potential cost reductions through optimization of
AIT [33].
Of course, choosing the right allergen (s) for AIT is es-
sential. Sastre et al. looked at whether a molecular diagno-
sis would change the allergen prescription in AIT in a
group of 141 patients with pollen-induced AR [43]. The
patients were tested with SPTs and the ISAC® microarray-
based panel of allergens before and after the prescription
of AIT. In 54% of cases, the molecular diagnosis changed
the indication for AIT. The degree of agreement varied ac-
cording to the allergen in question (being higher for olive
and cypress extracts and lower for grass pollen extract).
The authors considered that the poor levels of agreement
were due to the prescription of AIT on the basis of SPTs
with a substantial proportion of false-negative results. The
degree of agreement was also worsened by the presence of
sensitization to profilin and/or polcalcin.
Conclusions
Characterization of sensitizations
Polysensitization is highly prevalent in patients being
treated for allergies, although the prevalence depends on
the population and the region and changes over time. A
supposedly monosensitized patient may merely have
been screened against a small or inappropriate panel of
allergens and thus the presence of a clinically relevant
allergy to another allergen should still be considered if
supported by clinical evidence. Hence, we suggest that
there is a need for (i) further standardization of SPT al-
lergen panels used in the same geographical or climatic
area, (ii) an increase in the number of allergens used in
SPT panels, (iii) the customization of the allergen panels
for particular geographical or climatic areas and (iv) use
of CRD in patients with positive SPTs for two or more
related allergens.The prevalence of polysensitization
An overall assessment of the epidemiological and clinical
trial data suggests that between 50% and 80% of patients
consulting allergists are polysensitized. The exact preva-
lence depends on the population and the region. Patients
tend to gain sensitizations over time.
The relationships between polysensitization, polyallergy
and treatment efficacy
The definitions of monosensitization, paucisensitization
and polysensitization are of clinical relevance. Polysensi-
tized patients do not necessarily have polyallergy, whereas
all polyallergic patients will be polysensitized. Polysensiti-
zation develops over time and may be associated with dis-
ease severity. The current evidence suggests that single-
allergen AIT is effective in polysensitized (but not neces-
sarily polyallergic) patients. The role of CRD for guiding
treatment should also be investigated. A detailed molecu-
lar diagnosis will add value when determining whether
AIT is appropriate for a given patient and, if so, which al-
lergen (s) should be administered. However, there is
clearly a need for well-powered, specifically designed clin-
ical studies comparing the efficacy and safety of (i) single-
allergen AIT, (ii) AIT with two or three allergen extracts
(preferably delivered separately and at high dosage levels)
and (iii) AIT with a high number of allergen extracts (e.g.
8 to 10). Overall, there is a need to develop algorithms or
decision trees for the choice of the allergen (s) to be in-
cluded in AIT for polyallergic patients.
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